The FDA has authorized Minder, the first implantable continuous electroencephalogram monitor, offering long-term brain activity tracking for improved epilepsy management, available in the U.S.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
“Approval of an immediate-use intranasal diazepam treatment that can be given at any time—even while a child is actively seizing—in this young age group is an important advance for the epilepsy community.”
Researchers found Oropouche virus to be underreported during a large-scale study across Latin America, with climate emerging as the primary driver of transmission risk.
"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.